PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
BIOX vs. FULC
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between BIOX and FULC is 0.14, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

BIOX vs. FULC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bioceres Crop Solutions Corp. (BIOX) and Fulcrum Therapeutics, Inc. (FULC). The values are adjusted to include any dividend payments, if applicable.

-50.00%0.00%50.00%100.00%SeptemberOctoberNovemberDecember2025
12.85%
-70.67%
BIOX
FULC

Key characteristics

Sharpe Ratio

BIOX:

-1.22

FULC:

-0.49

Sortino Ratio

BIOX:

-2.02

FULC:

-0.04

Omega Ratio

BIOX:

0.76

FULC:

0.99

Calmar Ratio

BIOX:

-0.79

FULC:

-0.50

Martin Ratio

BIOX:

-1.45

FULC:

-0.93

Ulcer Index

BIOX:

33.77%

FULC:

48.68%

Daily Std Dev

BIOX:

40.12%

FULC:

93.08%

Max Drawdown

BIOX:

-62.25%

FULC:

-92.70%

Current Drawdown

BIOX:

-57.19%

FULC:

-87.21%

Fundamentals

Market Cap

BIOX:

$414.10M

FULC:

$213.60M

EPS

BIOX:

$0.02

FULC:

-$0.29

Total Revenue (TTM)

BIOX:

$300.91M

FULC:

$80.00M

Gross Profit (TTM)

BIOX:

$125.90M

FULC:

$62.26M

EBITDA (TTM)

BIOX:

$36.85M

FULC:

$3.76M

Returns By Period

In the year-to-date period, BIOX achieves a 12.66% return, which is significantly higher than FULC's -15.74% return.


BIOX

YTD

12.66%

1M

7.03%

6M

-32.31%

1Y

-45.89%

5Y*

6.74%

10Y*

N/A

FULC

YTD

-15.74%

1M

-22.05%

6M

-58.53%

1Y

-48.90%

5Y*

-25.36%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

BIOX vs. FULC — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BIOX
The Risk-Adjusted Performance Rank of BIOX is 33
Overall Rank
The Sharpe Ratio Rank of BIOX is 11
Sharpe Ratio Rank
The Sortino Ratio Rank of BIOX is 22
Sortino Ratio Rank
The Omega Ratio Rank of BIOX is 33
Omega Ratio Rank
The Calmar Ratio Rank of BIOX is 55
Calmar Ratio Rank
The Martin Ratio Rank of BIOX is 66
Martin Ratio Rank

FULC
The Risk-Adjusted Performance Rank of FULC is 2525
Overall Rank
The Sharpe Ratio Rank of FULC is 2020
Sharpe Ratio Rank
The Sortino Ratio Rank of FULC is 3131
Sortino Ratio Rank
The Omega Ratio Rank of FULC is 3131
Omega Ratio Rank
The Calmar Ratio Rank of FULC is 1717
Calmar Ratio Rank
The Martin Ratio Rank of FULC is 2525
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

BIOX vs. FULC - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Bioceres Crop Solutions Corp. (BIOX) and Fulcrum Therapeutics, Inc. (FULC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for BIOX, currently valued at -1.22, compared to the broader market-2.000.002.00-1.22-0.49
The chart of Sortino ratio for BIOX, currently valued at -2.02, compared to the broader market-4.00-2.000.002.004.00-2.02-0.04
The chart of Omega ratio for BIOX, currently valued at 0.76, compared to the broader market0.501.001.502.000.760.99
The chart of Calmar ratio for BIOX, currently valued at -0.79, compared to the broader market0.002.004.006.00-0.79-0.50
The chart of Martin ratio for BIOX, currently valued at -1.45, compared to the broader market0.0010.0020.00-1.45-0.93
BIOX
FULC

The current BIOX Sharpe Ratio is -1.22, which is lower than the FULC Sharpe Ratio of -0.49. The chart below compares the historical Sharpe Ratios of BIOX and FULC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-2.00-1.000.001.002.00SeptemberOctoberNovemberDecember2025
-1.22
-0.49
BIOX
FULC

Dividends

BIOX vs. FULC - Dividend Comparison

Neither BIOX nor FULC has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

BIOX vs. FULC - Drawdown Comparison

The maximum BIOX drawdown since its inception was -62.25%, smaller than the maximum FULC drawdown of -92.70%. Use the drawdown chart below to compare losses from any high point for BIOX and FULC. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%-30.00%SeptemberOctoberNovemberDecember2025
-57.19%
-87.21%
BIOX
FULC

Volatility

BIOX vs. FULC - Volatility Comparison

Bioceres Crop Solutions Corp. (BIOX) has a higher volatility of 17.47% compared to Fulcrum Therapeutics, Inc. (FULC) at 14.44%. This indicates that BIOX's price experiences larger fluctuations and is considered to be riskier than FULC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%100.00%SeptemberOctoberNovemberDecember2025
17.47%
14.44%
BIOX
FULC

Financials

BIOX vs. FULC - Financials Comparison

This section allows you to compare key financial metrics between Bioceres Crop Solutions Corp. and Fulcrum Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab